The new research, published in Frontiers in Endocrinology, compared ultrasound-guided thermal ablation with conventional surgical resection in patients with small papillary thyroid carcinomas confined to the danger triangle. Papillary thyroid carcinoma is the most common thyroid malignancy, accounting for more than 80 percent of all thyroid cancers, and most of these tumors are indolent—slow-growing enough that treatment decisions hinge on balancing cure against harm. The danger triangle, however, raises the stakes: its cramped geometry complicates both surgery and ablation, and earlier studies had only short-term data to justify treating tumors there with heat rather than resection.

The study team reviewed 470 patients treated at two Chinese hospitals between September 2016 and April 2020 and, after applying strict criteria, analyzed 194 of them: 103 who received thermal ablation and 91 who had surgery. Because patients were not randomized, the researchers used propensity score matching to balance the two groups on age, sex, tumor size and volume, hormone levels, and precise anatomical distances—such as how far the tumor sat from the tracheoesophageal groove. After matching, 84 patients per group remained, and the groups were statistically indistinguishable at baseline.

The ablation technique itself is a study in precision. Performed under local anesthesia and real-time ultrasound guidance, the procedure uses either radiofrequency or microwave energy delivered through a thin electrode inserted through the isthmus of the gland. To protect the recurrent laryngeal nerve, trachea, and esophagus, the team continuously infused 5 percent dextrose solution around the tumor—a technique called hydrodissection that pushes vulnerable structures at least 5 millimeters away from the heat zone. Operators then used a low-power, moving-shot technique to destroy the tumor plus a margin of at least 3 millimeters, sparing the capsule where margins could not be extended safely. Immediate contrast-enhanced ultrasound confirmed that every treated lesion showed no residual blood flow, a 100 percent technical success rate.

Surgery, by contrast, followed Chinese national consensus guidelines and included prophylactic central neck dissection in all cases—a precaution reflecting concern that tumors abutting the posterior capsule carry a higher risk of hidden lymph node spread. Most surgical patients (88 percent) underwent lobectomy; the rest had total thyroidectomy, often driven by family history of thyroid cancer. The mean incision measured about 7.2 centimeters, compared with a 1-to-2-millimeter puncture for ablation.

After a median follow-up of roughly five and a half years in both groups, the oncologic results were strikingly similar. Overall disease progression occurred in 6.0 percent of the ablation group versus 4.8 percent of the surgery group—a difference with no statistical significance. Regional lymph node metastasis appeared in 1.2 percent of ablated patients and 3.6 percent of surgical patients; local tumor progression at the treatment site occurred in 3.6 percent versus 1.2 percent. Disease-free survival was 94 percent after ablation and 95.2 percent after surgery. No patient in either group developed distant metastasis. Notably, the ablation zone vanished completely in 94 percent of treated nodules over time, with smaller T1a tumors disappearing faster (a median of 24 months) than the larger T1b tumors (36 months).

The safety picture told a different story. Total complications were nearly three times more common after surgery: 16.7 percent versus 6.0 percent, a statistically significant difference. Every major complication occurred in the surgical group—four cases of permanent hoarseness from nerve injury and two cases of permanent hypoparathyroidism, both in patients who had total thyroidectomy. In the ablation group, the only complications were five cases of transient hoarseness, all of which resolved within six months without treatment. Among the smallest tumors (T1a, one centimeter or less), the safety gap widened further: 3.0 percent complication rate for ablation versus 15.3 percent for surgery. The authors caution that this subgroup finding is exploratory, given the small number of events.

Efficiency metrics favored ablation across the board. The average procedure took 23 minutes versus 82 minutes for surgery. Hospital stay averaged one day versus 3.3 days. Estimated blood loss was about 2 milliliters versus nearly 20. For elderly patients or those with comorbidities, the authors argue, such a short, low-risk pathway reduces not only perioperative danger but also healthcare resource use. And because ablation preserves the gland, patients avoid lifelong thyroid hormone replacement—a meaningful quality-of-life advantage that surgery cannot offer unless only one lobe is removed.

The study’s authors are careful about what the data do and do not show. Because no formal sample size calculation was performed, the similar outcomes cannot be formally interpreted as proof of equivalence or non-inferiority—a statistical distinction that matters. The retrospective design leaves room for unmeasured confounders such as patient preference and frailty. The ablation cohort mixed radiofrequency and microwave devices, and every ablation was performed by radiologists with more than a decade of experience, limiting generalizability to lower-volume centers. Differing follow-up schedules—ablation patients were imaged more often early on—could also bias event detection. Still, the authors note that progression rates rose only slightly from their earlier three-year report (from 4.4 to 6.0 percent in the ablation group), confirming durable oncologic stability.

The significance of the work lies in where it lands. The danger triangle has been a holdout region, where the proximity of nerve, trachea, and esophagus made many clinicians reluctant to ablate. By pairing hydrodissection with low-power, short-electrode techniques and rigorous ultrasound surveillance, this study shows that the same rules that made ablation safe elsewhere in the gland can be stretched into its most hostile corner. The authors call for multicenter randomized trials to confirm the findings, but for now the message is concrete: for carefully selected patients with small papillary thyroid carcinomas in the danger triangle, a needle, some dextrose, and a steady ultrasound-guided hand can match the oncologic results of surgery while sparing the voice, the parathyroids, and most of a hospital week.

Subject of Research: Long-term comparison of thermal ablation versus surgical resection for T1N0M0 papillary thyroid carcinoma in the thyroid danger triangle

Article Title: Long term (over five-year) outcomes of thermal ablation vs surgical resection for T1N0M0 papillary thyroid carcinoma in danger triangle: a propensity-matched dual-center study

Article References: Zhang, D., Chen, S., Yang, J., Qiu, Y., Zhao, Z., Tang, L., Hu, T., Yu, M.-A., & Wu, S. (2026). Long term (over five-year) outcomes of thermal ablation vs surgical resection for T1N0M0 papillary thyroid carcinoma in danger triangle: a propensity-matched dual-center study. Frontiers in Endocrinology, 17, Article 1887923. https://doi.org/10.3389/fendo.2026.1887923

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1887923

Keywords: papillary thyroid carcinoma, thermal ablation, radiofrequency ablation, thyroid danger triangle, propensity score matching, disease-free survival, recurrent laryngeal nerve, hydrodissection, thyroid surgery, minimally invasive treatment, lymph node metastasis, complication rates

The clinical stakes are considerable. Hepatocellular carcinoma, the most common primary liver cancer, almost always arises in livers scarred by cirrhosis, and the same scarring that produced the tumor limits how much healthy tissue can be sacrificed during treatment. For patients who are not surgical candidates, percutaneous microwave ablation has become a mainstay: an antenna is threaded into the tumor, typically under ultrasound or CT guidance, and dielectric heating coagulates the lesion while sparing the surrounding parenchyma. Technical success depends on complete coverage of the tumor by the ablation zone, and most interventional radiologists aim for an ablative margin of at least five millimeters in every direction. Fall short of that margin, and residual tumor cells at the edge of the zone can seed a local recurrence. Manufacturers therefore publish charts that translate power and time into expected ablation dimensions based on in vivo liver models, and clinicians use those numbers to plan each burn.

The Bergamo team set out to test whether those chart numbers hold up in the real world of cirrhotic livers. They assembled a single-center retrospective cohort of patients with cirrhosis and BCLC stage 0, A, or B hepatocellular carcinoma who underwent microwave ablation between November 28, 2022, and June 30, 2025, with a database cutoff of March 31, 2026. After applying strict inclusion and exclusion criteria, the analytic cohort comprised 29 patients, all male by chance, who underwent 29 procedures treating 43 lesions with a single microwave platform, the Medtronic Emprint HP system. Every lesion had both an immediate post-procedural volume measurement and a one-month follow-up measurement, allowing the researchers to compare reality against prediction twice. Lesions were classified by size, small up to 25 millimeters or larger lesions up to 30 millimeters, and by location, either within one centimeter of the liver capsule or within one centimeter of a hepatic or portal vein branch.

The measurement technique was deliberately straightforward. Using a commercial workstation, a radiologist measured three orthogonal diameters of each ablation zone on contrast-enhanced CT or CT hepatic arteriography performed immediately after the procedure, and applied the ellipsoid formula to convert those diameters into a volume. Power settings were selected from the manufacturer’s in vivo liver chart according to lesion dimensions and the intended margin, with most lesions treated at 100 watts and a minority at 150 watts, and recorded durations ranging from one to ten minutes with a median of six. The primary comparison was the difference between the measured volume and the chart-predicted volume, so a negative number meant the actual ablation fell short of the promise. Because some patients contributed multiple lesions, the team used a cluster-aware statistical approach, a linear mixed-effects model with a patient-level random intercept, and validated the results with a sensitivity analysis restricted to one lesion per patient.

The numbers told a consistent and sobering story. Across all 43 lesions, the mean chart-predicted volume was 23.4 cubic centimeters, while the mean measured volume on immediate imaging was just 15.1 cubic centimeters, a shortfall of roughly 35 percent. The cluster-adjusted mean bias was minus 8.50 cubic centimeters, with a 95 percent confidence interval running from minus 10.28 to minus 6.71, and the limits of agreement stretched from minus 18.63 to plus 1.64 cubic centimeters, meaning individual lesions could deviate from prediction by amounts that would matter enormously at the margin. A Wilcoxon signed-rank test confirmed the difference was highly significant, and the one-lesion-per-patient sensitivity analysis reproduced the bias almost exactly at minus 8.44 cubic centimeters. Only two lesions, both subcapsular, bucked the trend and came in larger than their chart values.

The statistical texture of the disagreement is as important as its average. The researchers detected proportional bias, with a slope of 0.34 indicating that the measured-minus-predicted gap grew as the predicted volume increased, and they found heteroscedasticity, meaning the scatter of differences widened for larger ablations. Together, these findings rule out the tempting quick fix of a single uniform correction factor that could be applied to every chart entry. In other words, clinicians cannot simply assume the chart overestimates by a fixed percentage; the error behaves differently depending on the size of the planned ablation, which complicates procedural planning and underscores the need for careful post-procedural verification rather than blind trust in lookup tables.

Why would microwave energy underperform in cirrhotic tissue? The authors point to biologically plausible mechanisms rooted in the physics of dielectric heating. Microwave antennas deposit energy by oscillating water molecules, and the efficiency of that deposition depends on the tissue’s electrical conductivity and thermal properties. Experimental work has shown that these dielectric properties differ measurably between normal liver, cirrhotic liver, and tumor tissue, and the fibrosis, altered perfusion, and changed water content of a cirrhotic liver can impede the spread of heat. Notably, the shortfall in the Bergamo cohort remained relatively constant across lesion sizes and locations, which the authors interpret as a uniform impairment of thermal conduction in the cirrhotic substrate rather than a size- or position-dependent effect. Their series also included an unusual concentration of difficult anatomy: every lesion was either subcapsular or perivascular, reflecting the referral patterns of a tertiary center.

The two outliers that exceeded their chart predictions offer an intriguing counterpoint. Both were small subcapsular lesions that showed transient volumetric expansion on immediate imaging before shrinking substantially at one month. The authors speculate that a lower degree of fibrosis, or excess liver hydration from intra-arterial contrast administration during CT hepatic arteriography, may have improved microwave diffusion in these cases, since better-hydrated tissue generally conducts microwave energy more effectively. The observation, while anecdotal, reinforces the central physical insight: the ablation zone is not a fixed product of the device settings but an emergent result of the interaction between delivered energy and the specific tissue it encounters.

The study also tracked how ablation zones evolve over time, a dimension that has received little attention in cirrhotic patients. Mean volume fell from 15.1 to 12.66 cubic centimeters between the immediate and one-month imaging, a cluster-adjusted change of minus 2.34 cubic centimeters, with a median within-lesion shrinkage of 15.9 percent. Thirty-seven lesions decreased and six increased. Meanwhile, clinical outcomes were strong by conventional measures: immediate technical success, defined as visual inclusion of the tumor within the non-enhancing ablation zone with an intended five-millimeter margin, was achieved in all 43 lesions, and local tumor progression occurred in five lesions, or 11.6 percent, over a median follow-up of 13 months. Four minor complications, two pneumothoraces and two mild hemoperitoneums, occurred across 29 procedures and were managed conservatively.

The authors are careful about the limits of their evidence. The study was retrospective, single-center, and non-randomized, involved one microwave platform and an all-male cohort, and lacked a non-cirrhotic comparator group. Quantitative fibrosis measurements and detailed liver-disease variables were unavailable, precluding mechanistic analysis, and volumes were measured by a single radiologist without formal reproducibility testing, using an ellipsoid formula that may not capture irregular ablation zones. Still, the message for practice is clear enough that the authors argue for adjusted ablation parameters in cirrhotic patients, potentially increasing power or duration within safety limits to achieve more adequate margins, since larger margins are known to reduce local recurrence. Their longer-term vision is more ambitious: liver-specific ablation charts that incorporate tissue perfusion and stiffness data, so that the lookup table reflects the actual liver on the table rather than an idealized one. Until such charts exist, the study suggests, the immediate post-procedural scan remains the only honest referee of whether the burn was big enough.

Subject of Research: Agreement between manufacturer-predicted and measured ablation volumes after microwave ablation of hepatocellular carcinoma in cirrhotic livers

Article Title: Manufacturer-chart versus measured ablation volumes after microwave ablation of hepatocellular carcinoma in cirrhotic livers: a retrospective cohort study

Article References: Muglia, R., Martins de Mattos, K. D., Carbone, F. S., Bertuletti, M., Dulcetta, L., Gargiulo, C., Marra, P., & Sironi, S. (2026). Manufacturer-chart versus measured ablation volumes after microwave ablation of hepatocellular carcinoma in cirrhotic livers: a retrospective cohort study. CVIR Oncology, 2(1), Article 34. https://doi.org/10.1007/s44343-026-00066-y

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00066-y

Keywords: microwave ablation, hepatocellular carcinoma, cirrhosis, ablation volume, manufacturer chart, ablative margin, interventional radiology, liver cancer, Bland-Altman analysis, thermal ablation, CVIR Oncology, retrospective cohort

The review, authored by Neetu Singh of King George’s Medical University in Lucknow, India, synthesizes decades of progress in computational bioheat transfer and maps a clear trajectory toward what she calls precision, uncertainty-aware, patient-adaptive thermal oncology. At the heart of the analysis is a sobering assessment of the field’s foundational equation. Formulated by Harry Pennes in 1948 from forearm temperature measurements, the Pennes bioheat equation describes tissue heating as a balance of conductive heat transfer, blood perfusion modeled as a simple heat sink proportional to the arterial-tissue temperature difference, and externally applied energy from the treatment device. It remains the reference standard against which every more sophisticated model is judged.

The problem is that the Pennes equation makes assumptions that break down precisely where it matters most clinically. Its most serious weakness is the treatment of blood perfusion as a spatially uniform, directionless sink term. In reality, large vessels such as the portal and hepatic veins act as powerful, directional heat drains. When a liver tumor sits adjacent to one of these vessels, convective heat removal along the vessel axis distorts the temperature field and warps the ablation lesion into shapes that a spatially averaged perfusion term simply cannot reproduce. Comparisons cited in the review show that near major vessels, discrepancies between Pennes-based predictions and vascular-resolved simulations can exceed fifteen to twenty-five percent in predicted ablation margins, a range large enough to compromise oncologic safety.

Rapid heating exposes further cracks. Fourier’s law, embedded in the classical formulation, assumes heat propagates instantaneously, an acceptable fiction at macroscopic scales but questionable during the steep gradients and short energy pulses of high-power microwave and laser ablation. To address this, researchers have turned to non-Fourier formulations such as the dual-phase-lag model, which introduces two relaxation times: one governing how quickly heat flux responds to an imposed temperature gradient, and another accounting for the delayed development of the gradient itself. When both lag parameters approach zero, the equation gracefully collapses back to classical Fourier conduction, but during fast transient heating it better captures finite thermal propagation speeds, particularly near applicator tips and microvascular interfaces.

Tissue properties themselves are anything but static. Between forty degrees Celsius and ablation temperatures, thermal conductivity, electrical conductivity, and dielectric behavior vary substantially and nonlinearly. The review highlights studies showing that electrical conductivity in hepatic tissue rises by roughly one and a half to two percent per degree Celsius up to one hundred degrees before plummeting when vaporization begins. Encouragingly, comparisons of different piecewise temperature-dependent conductivity formulations found that predicted lesion dimensions remained largely consistent despite differences in functional form, supporting the use of simplified but physiologically informed models. The payoff for getting this right is dramatic: expanded electromagnetic-thermal models incorporating sigmoidal temperature-dependent dielectric properties reduced mean temperature prediction errors during microwave ablation from roughly twenty-seven to thirty-two percent down to about four percent when validated experimentally.

The review also introduces a three-axis taxonomy for judging any bioheat model: physiological fidelity, computational tractability, and clinical validation maturity. This framing exposes an uncomfortable trade-off. In moderately perfused tissues, the humble Pennes equation deviates by less than five to ten percent from vascular-resolved simulations and runs in minutes. Vascular-resolved and multiphysics frameworks, which couple electromagnetic, acoustic, or optical solvers directly to thermal equations, offer far better fidelity in perfusion-dominated regimes but can demand hours to days of computation. Machine learning surrogates compress those runtimes to seconds, yet their reliability collapses outside the distribution of their training data, particularly under extreme conditions such as tissue vaporization or charring.

Predicting temperature, however, is only half the battle. Clinical outcomes depend on cumulative cellular injury, which most frameworks capture through the Arrhenius injury integral, an exponential damage model in which a value of one corresponds to roughly sixty-three percent cell death, the conventional threshold for coagulative necrosis. A complementary empirical metric, cumulative equivalent minutes at forty-three degrees Celsius, quantifies sub-lethal thermal exposure in hyperthermia contexts. Intriguingly, emerging evidence suggests thermal therapies do more than cook cells: sub-lethal heating can alter tumor microenvironmental signaling, vascular permeability, and immune cell recruitment, hinting that future models may need to integrate thermal physics with systems-level immunology.

Patient-specificity is the other pillar of the transformation. Modern planning workflows reconstruct anatomy from MRI and CT scans, explicitly capturing tumor geometry, applicator positioning, and proximity to dangerous vessels. Imaging-derived perfusion estimates personalize blood flow parameters, while MR thermometry maps temperature in real time during treatment, providing a feedback loop for correcting models on the fly. Hybrid analytical-numerical frameworks validated against MR thermometry have demonstrated that in ex vivo experiments, eighty-three to ninety-eight percent of voxels achieved root-mean-square temperature errors of one degree Celsius or less, with total simulation and image-alignment times below 0.3 seconds per repetition, fast enough for genuine intraoperative use.

None of this will reach patients without regulatory credibility. The review emphasizes the FDA-recognized ASME V&V 40 standard, which assesses model credibility relative to context of use, verification rigor, validation evidence, and uncertainty quantification. Because bioheat predictions directly influence ablative safety margins, regulators demand demonstration that a model’s errors are understood, bounded, and communicated. Reporting prediction intervals alongside nominal temperature estimates, rather than single deterministic numbers, is increasingly viewed as essential for both regulatory approval and clinician trust. Validation itself follows a hierarchy, from tissue-mimicking phantoms through animal tumor models to clinical datasets, though differences in scale and perfusion characteristics across these platforms complicate direct comparison.

The destination, Singh argues, is the patient-specific digital twin: a physics-constrained, machine-learning-accelerated model of an individual patient’s tumor that evolves in real time as treatment proceeds. Closed-loop platforms combining MR thermometry, predictive bioheat solvers, and adaptive control algorithms would dynamically adjust energy delivery to compensate for perfusion changes and unanticipated heat-sink effects, with particular promise in perfusion-rich organs like the liver and the margin-intolerant brain. Three barriers stand in the way: uncertainty in patient-specific parameters such as perfusion and vaporization thresholds, the need for sub-second computational performance during intervention, and rigorous verification and validation consistent with regulatory expectations. Overcome them, and computational bioheat modeling will complete its evolution from a retrospective planning tool into a live, adaptive decision-support system at the heart of precision thermal oncology.

Subject of Research: Computational bioheat transfer modeling for minimally invasive cancer thermal ablation therapies

Article Title: Advanced computational approaches for bioheat transfer in minimally invasive cancer thermal therapies

Article References: Singh, N. (2026). Advanced computational approaches for bioheat transfer in minimally invasive cancer thermal therapies. Frontiers in Thermal Engineering, 6, Article 1798897. https://doi.org/10.3389/fther.2026.1798897

Image Credits: AI Generated

DOI: 10.3389/fther.2026.1798897

Keywords: bioheat transfer, thermal ablation, Pennes bioheat equation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, laser interstitial thermal therapy, physics-informed machine learning, MR thermometry, vascular heat sink, Arrhenius thermal damage, digital twin

The research, led by Susanta Kumar Swain of the Odisha Department of Health and Family Welfare together with colleagues from the Acharya Harihar Post Graduate Institute of Cancer, the Indian Council of Medical Research, and the Norway India Partnership Initiative, set out to test whether a home-based screening model could be delivered through the existing public health system rather than through parallel, donor-driven structures. The team implemented what is known as a screen–triage–treat approach in Thoria Sahi, a settlement in Cuttack, targeting women between the ages of 30 and 65. Data collected between October 2022 and September 2023 were analyzed to measure screening coverage, HPV positivity, follow-up behavior, and treatment outcomes.

The technical logic of the model rests on the biology of the disease itself. Virtually all cases of cervical cancer are caused by persistent infection with high-risk types of human papillomavirus, and detecting the virus’s DNA in cervical cells is a more sensitive screening method than conventional cytology. Crucially, self-collected vaginal samples have been shown in multiple international studies to perform nearly as well as clinician-collected specimens for HPV testing. That property makes self-sampling a powerful tool for communities where cultural norms, modesty concerns, time constraints, and distrust of pelvic examinations keep women away from clinics. In Thoria Sahi, the program leaned on Accredited Social Health Activists, or ASHAs, the frontline community health workers who form the backbone of India’s rural and urban health outreach, to mobilize eligible women and support them in collecting samples at home.

The numbers from the pilot are striking. Of 6,436 women identified as eligible, 4,896 completed screening, a coverage rate of 76 percent. Among those screened, 322 women, or 7 percent, tested positive for high-risk HPV, a prevalence consistent with expectations for a population that had never previously been screened. Each positive result triggered a referral to an Urban Primary Health Centre, where nurses trained in visual inspection with acetic acid, or VIA, performed triage. This two-step design reflects current World Health Organization guidance, which favors HPV-based primary screening followed by a same-day triage test so that women with likely precancerous lesions can be treated immediately rather than lost to follow-up.

Here the pilot encountered the challenge that has undermined many screening programs before it: the follow-up gap. Despite counselling, only 42 percent of HPV-positive women, 135 of 322, returned to a health centre for VIA triage. Of those who did, 38.5 percent were VIA-positive, indicating likely precancerous changes. Among VIA-positive women, 81 percent received thermal ablation on the spot, a low-cost outpatient procedure that uses a heated probe to destroy abnormal cervical tissue. The remainder were referred for colposcopy, biopsy, and further management in line with national guidelines. In total, the program identified and appropriately managed seven cases of precancerous lesions and one case of micro-invasive carcinoma, detections that in an unscreened population would likely have surfaced only years later as advanced, difficult-to-treat disease.

The authors are candid about what the attrition at the triage stage means. A screening program is only as strong as its weakest link, and the drop from 322 HPV-positive women to 135 who completed triage illustrates that testing alone does not guarantee protection. Community-based follow-up by ASHAs confirmed that women who did receive treatment adhered to it and remained well, which suggests the treatment pathway itself functioned smoothly once patients entered it. The bottleneck lay in getting women from a positive home test to the clinic door, a gap shaped by fear, stigma, household obligations, and the practical costs of travel and waiting time. The study’s central lesson, as the authors put it, is that referral and treatment systems must be strengthened from the outset, not retrofitted after a screening campaign has generated a backlog of positive results.

Why does this matter on a global scale? The World Health Organization has set an ambitious goal of eliminating cervical cancer as a public health problem, a target that requires 70 percent of women to be screened with a high-performance test at least twice in their lives by 2030. India, with its enormous population and historically low screening uptake, is pivotal to that effort. National Family Health Survey 5 data showing screening coverage below 2 percent underline how far the country is from the target, and conventional clinic-based approaches have repeatedly failed to close the gap. Self-sampling flips the equation by removing the most intimidating step, the pelvic examination, and by bringing the test to women rather than requiring women to come to the test.

The Odisha pilot is also notable for what it did not do: it did not build a parallel health system. The model was embedded in the public health infrastructure, using government ASHAs for mobilization and follow-up, Urban Primary Health Centres for triage, and designated treatment centres for colposcopy and surgical management. That integration matters for scalability, because vertical programs funded by short-term grants often collapse when the funding ends. By demonstrating that a screen–triage–treat cascade can run through existing public machinery, the study offers a template that state health departments could adapt, provided they invest in supply chains for HPV test kits, laboratory capacity for DNA testing, and training for frontline workers.

The technical details of the cascade deserve attention for anyone designing similar programs. HPV-DNA testing detects the genetic material of high-risk virus types, identifying women at risk before any cellular abnormality appears, which gives clinicians a longer window for intervention than cytology-based screening. VIA, the triage step used here, involves applying dilute acetic acid to the cervix and looking for acetowhite areas that suggest precancerous change; it is inexpensive, requires minimal equipment, and allows immediate see-and-treat decisions. Thermal ablation is appropriate for lesions that meet size and location criteria and is far simpler than excisional procedures, making it feasible at primary care level. The 38.5 percent VIA positivity among HPV-positive women in this pilot is within the range reported in comparable Indian studies, reflecting the fact that most HPV infections clear spontaneously and only a minority progress to lesions.

The study received no external funding and was approved by the State Research and Ethical Committee of the Odisha Department of Health and Family Welfare, with written informed consent obtained from all participants. Its findings arrive at a moment when HPV vaccination is expanding and molecular diagnostics are becoming cheaper, creating a rare window in which elimination of cervical cancer in low-resource settings looks technically achievable. The Odisha experience shows that when the test comes to the woman, coverage can soar; the unfinished work lies in ensuring that a positive result is followed swiftly by triage and treatment. If health systems can close that loop, home-based self-sampling could become one of the most consequential public health tools of the decade, turning a disease that kills quietly into one that is caught early, treated cheaply, and ultimately prevented.

Subject of Research: Home-based HPV-DNA self-sampling for cervical cancer screening in underserved urban communities in India

Article Title: Improving coverage of cervical cancer screening for hard-to-reach women: lessons learned from piloting an innovative home-based screening model in Odisha, India

Article References: Swain, S. K., Nayak, B., Hariprasad, R., Rattan, R., Srivastava, A. K., Bhargava, S., & Biswal, D. K. (2026). Improving coverage of cervical cancer screening for hard-to-reach women: lessons learned from piloting an innovative home-based screening model in Odisha, India. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15839-7

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15839-7

Keywords: cervical cancer, HPV-DNA testing, self-sampling, cancer screening, Odisha, India, ASHA health workers, screen-triage-treat, thermal ablation, VIA, public health, urban slums

The clinical stakes are considerable. Thermal ablation, whether by radiofrequency or microwave energy, destroys tumor tissue by heating it through an applicator placed percutaneously into the lesion. Precise placement of that applicator is vital to achieve sufficient ablation margins around the tumor and to avoid injuring healthy structures nearby. Ventilation-induced organ movement complicates this task in several ways: for stereotactic puncture techniques, control of respiratory motion strongly influences accuracy, and for software that confirms ablation completeness by fusing pre- and post-ablation images, respiratory movement can render co-registration between image sets genuinely challenging. When the target shifts several millimeters with each breath, even sophisticated navigation systems struggle to guarantee that the entire tumor and a safety halo around it have been treated.

Historically, the preferred technique for stabilizing the liver has been one-lung ventilation, in which a double-lumen tube allows the right lung to be deliberately deflated while the left lung is ventilated. With the right lung collapsed, the liver loses much of the mechanical push from the diaphragm on that side, and the acoustic window for tumors near the top of the liver also improves. But this strategy is far from benign. It is profoundly non-physiological: the ventilated lung may suffer injury from high end-inspiratory volumes, oxidative stress, and increased perfusion, while the deflated lung is exposed to atelectasis-related ischemia-reperfusion injury and re-expansion damage when it is finally reinflated. The larger dimensions of the double-lumen tube increase the risk of laryngeal injury, and patient factors such as cardiopulmonary comorbidity, obesity, and advanced age can reduce tolerance of one-lung ventilation altogether, sometimes forcing the team to abandon the technique mid-procedure because of hypoxia or hemodynamic instability.

An increasingly popular alternative is high-frequency jet ventilation, or HFJV, which delivers very small pulses of gas at extremely high rates, in this study at the manufacturer’s default setting of 600 breaths per minute. Because each pulse is tiny, the diaphragm barely moves, and the liver stays nearly still. HFJV has been shown in previous work to provide minimal ventilation-induced liver movement and is now widely used for image-guided ablation. It is not, however, a universal solution. It requires specialized equipment and expertise that are not available everywhere, it can cause carbon dioxide retention during prolonged procedures, and it carries a risk of barotrauma if air cannot escape adequately. Patients with chronic obstructive pulmonary disease, obesity, or recent pneumothorax may be unsuitable candidates. One refinement, so-called double-jet ventilation, adds a normal-frequency jet component to improve carbon dioxide removal, but the researchers suspected this might come at the cost of increased liver movement.

To settle these questions, the Norwegian team conducted a single-center, non-randomized observational crossover study as a predefined substudy of the New Comet trial, a randomized controlled trial comparing surgical resection with thermal ablation of colorectal cancer liver metastases. Twenty patients scheduled for ablation between November 2022 and April 2024 each received all five ventilation modes in a predefined sequence, meaning every patient served as their own control. The modes were standard ventilation at 6 milliliters per kilogram of ideal body weight; a gentler low-tidal-volume, high-frequency strategy at 4 milliliters per kilogram delivered through a conventional endotracheal tube and ventilator; one-lung ventilation with right lung deflation; and high-frequency jet ventilation with and without the additional normal-frequency jet component. Anesthesia was maintained with target-controlled propofol and remifentanil infusions, with depth of anesthesia monitored by bispectral index, and rocuronium was given to facilitate intubation. The team aimed to keep arterial carbon dioxide below 8 kilopascals and oxygen saturation above 90 percent, with an adverse incident protocol ready if those targets were missed.

Measuring liver motion required careful technique. An experienced radiologist used ultrasound to record the cranio-caudal displacement of the inferior liver margin in both lobes: the left lobe was imaged in a sagittal plane in the epigastrium, while the right lobe was imaged through a parasagittal subcostal window as close as possible to the anterior axillary line. For each ventilation mode, the distance between the most cranial and most caudal positions of the inferior margin was measured across at least two respiratory cycles, with the transducer held in the same position throughout. The order of ventilation modes was not disclosed to the radiologist, although complete blinding proved impossible because jet ventilation produces characteristic noise and torso movement. In total, 200 measurements were collected, ten per patient, and the reliability of the method was verified by having two additional blinded radiologists independently analyze recorded ultrasound videos, with interobserver agreement assessed using intraclass correlation coefficients and Bland-Altman analysis against a predefined clinically acceptable variability of 2 millimeters or less.

The numbers were striking. Standard ventilation produced the greatest movement, with the left inferior liver margin traveling 5.8 millimeters and the right margin 7.3 millimeters during a respiratory cycle. The gentle low-tidal-volume, high-frequency strategy cut this to 4.0 millimeters on the left and 4.6 millimeters on the right, a meaningful reduction achieved with equipment available in any operating room. High-frequency jet ventilation was the clear winner, holding movement to just 1.2 millimeters on the left and a remarkable 0.5 millimeters on the right. Right-sided one-lung ventilation performed nearly as well for the right lobe, limiting movement of the right margin to 1.6 millimeters, though it offered far less benefit on the left, where the persistently ventilated left lung kept pushing the liver. Double-jet ventilation fell between HFJV and the conventional modes, confirming that adding the normal-frequency jet component to improve carbon dioxide removal does indeed increase liver movement on both sides.

Statistical analysis using linear mixed-effects models with a random intercept for each subject confirmed that these differences were robust. After log transformation of the movement data and Bonferroni correction for multiple testing, standard ventilation produced significantly greater movement than each of the other four methods on both sides, with all comparisons reaching significance except one-lung ventilation versus double-jet ventilation on the left side. Applying the predefined 2-millimeter clinical tolerance, only one-lung ventilation remained within that threshold of HFJV on the right side, while both double-jet ventilation and one-lung ventilation fell within tolerance on the left. Notably, gender, body mass index, and ideal body weight showed no statistically significant association with liver movement, and there was even a tendency toward less movement in the higher BMI group. Interobserver reliability was good, with 93.3 percent of paired video measurements within the 2-millimeter tolerance, and no intraoperative complications were registered during the study.

The authors are candid about the limitations. The sample of twenty patients was small, though the crossover design increased precision by allowing within-patient comparisons. The ventilation modes were applied in a fixed order, so order and carry-over effects cannot be excluded despite a standardized one-minute stabilization period, and neuromuscular blockade was not standardized, meaning residual rocuronium effect may have influenced diaphragmatic tone in later modes. The measurements were taken under short, controlled conditions rather than during prolonged ablation with a single strategy, and jet ventilation was delivered through the tracheal lumen of a double-lumen tube rather than a standard endotracheal tube, which the team chose deliberately to avoid the laryngeal risk of additional tube changes. Jet ventilation settings also vary across the literature, with many centers using lower frequencies of around 200 to 250 breaths per minute to limit hypercarbia over long procedures, potentially at the cost of more movement.

Even so, the practical message is clear and likely to influence practice well beyond Oslo. No single ventilation mode is universally optimal, and the choice should be individualized according to tumor location, patient comorbidities, and local expertise. High-frequency jet ventilation remains the preferred option when available and feasible, with one-lung ventilation as a strong alternative for selected right-sided tumors, particularly those in the hepatic dome where the deflated lung also improves the ultrasound window. For patients in whom advanced techniques are too risky or simply unavailable, gentle ventilation combined with timed breath holds offers a pragmatic middle path that meaningfully reduces motion compared with standard ventilation. The authors suggest that future research should explore whether more aggressive gentle ventilation strategies can further reduce movement safely over longer periods, and whether simple decision tools can be developed to guide ventilation strategy by incorporating tumor location, comorbidity, and the availability of advanced equipment. In a field where millimeters determine margins, knowing exactly what each breath costs is a powerful new piece of information.

Subject of Research: The effect of ventilation methods on liver movement during general anesthesia for thermal ablation of liver tumors

Article Title: The effect of ventilation methods on liver movement during general anesthesia for thermal ablation of liver tumors

Article References: Lappen, K. R., Hansen, I. S., Björk, I., Østergaard, D., Halvorsen, P. S., Orrem, H. L., Fretland, Å. A., Syversveen, T., & Espinoza, A. (2026). The effect of ventilation methods on liver movement during general anesthesia for thermal ablation of liver tumors. CVIR Oncology, 2(1), Article 32. https://doi.org/10.1007/s44343-026-00065-z

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00065-z

Keywords: thermal ablation, liver tumors, high-frequency jet ventilation, one-lung ventilation, gentle ventilation, liver movement, anesthesia, interventional radiology, colorectal liver metastases, ultrasound measurement, ventilation strategies, Oslo University Hospital

The stakes in this debate are anatomical. The thyroid gland is a small, butterfly-shaped structure wrapped around the windpipe, and it shares that crowded space with some of the most delicate structures in the human body. The recurrent laryngeal nerves, which control the vocal cords, run directly alongside the gland; injury to them can leave a patient with permanent hoarseness or breathing difficulties. The parathyroid glands, which regulate calcium, are similarly vulnerable. The trachea, esophagus, and major blood vessels of the neck all lie within millimeters of the thyroid capsule. For these reasons, tumors located adjacent to the capsule, the trachea, or the recurrent laryngeal nerve have traditionally been considered high-risk locations — and many guidelines and practitioners have treated them as contraindications to thermal ablation, reserving heat-based treatment only for tumors comfortably surrounded by normal thyroid tissue.

That conservative stance is now being re-examined. In 2024, an expert consensus broadened the potential indications for thermal ablation in papillary thyroid carcinoma, opening the door to treating tumors that were previously excluded on anatomical grounds. The Zhejiang University team, led by corresponding author Shiyan Li of the Department of Ultrasound, set out to test that expansion empirically. Their question was direct: when a small papillary thyroid carcinoma is classified as being in a high-risk location, does radiofrequency ablation performed by experienced hands produce outcomes that are meaningfully worse than ablation of tumors in low-risk locations? If the answer were no, the anatomical objection to ablation would lose much of its force.

To answer it, the researchers assembled a cohort of 268 patients with T1aN0M0 papillary thyroid carcinoma — the staging designation for tumors one centimeter or smaller with no lymph node involvement and no distant metastasis — who underwent radiofrequency ablation between January 2020 and April 2024. Each tumor was classified according to its position within the gland, dividing the cohort into a high-risk location group and a low-risk location group. All procedures were carried out by senior radiologists with more than five years of ablation experience, a detail the authors emphasize because operator skill is widely believed to be the decisive variable in whether tumors near critical structures can be treated safely. Patients were then followed until September 2025, yielding a median follow-up of 23.5 months.

The technical logic of radiofrequency ablation helps explain both its appeal and its risks. Under ultrasound guidance, a slender electrode is threaded through the skin and into the tumor, and an alternating electrical current is passed through the tissue. The resistance of the tissue generates frictional heat, creating a zone of coagulative necrosis that kills the cancer cells in place. Contrast-enhanced ultrasound is typically used afterward to confirm that the entire tumor has been devascularized. The technique avoids an incision, spares the remaining thyroid tissue, preserves thyroid function in most patients, and can often be performed with local anesthesia and same-day discharge. But near the trachea or the recurrent laryngeal nerve, the same heat that destroys the tumor can theoretically damage those structures, which is precisely why high-risk locations have been treated with such caution.

The primary endpoint of the study was the disease progression rate — whether the cancer grew, spread, or recurred during follow-up. The secondary endpoints covered the practical questions patients care about most: how much the tumor shrank, how often it disappeared completely, and how often complications occurred, along with postoperative anxiety and marked pain. The headline result was striking in its simplicity. Across the entire cohort, the complete tumor disappearance rate was 61.6 percent, and there was no statistically significant difference between the high-risk and low-risk groups, with a p value of 0.665. In other words, tumors nestled against the trachea or the nerve were just as likely to vanish after ablation as tumors in easy-to-treat positions.

Disease progression was rare in both groups, which is itself informative but also creates a statistical challenge. When an outcome is uncommon, conventional regression models can become unstable, so the researchers turned to Firth penalized logistic regression, a method designed to handle rare events and small cell counts. After adjusting for the baseline maximum tumor diameter, they found that high-risk location classification was not significantly associated with disease progression: the adjusted odds ratio was 1.77, with a 95 percent confidence interval stretching from 0.17 to 239.22 and a p value of 0.689. The extraordinarily wide confidence interval is worth pausing on. It reflects the fact that so few patients progressed at all that the data cannot precisely pin down the size of any effect — but the central estimate and the p value both indicate no detectable harm from treating tumors in high-risk positions.

The safety findings followed the same pattern. The researchers detected no significant associations between high-risk tumor location and the incidence of complications, postoperative anxiety, or marked pain. For a field in which fear of nerve injury and tracheal damage has long limited the use of ablation, that null result carries real weight. It suggests that, in the hands of operators with substantial experience, the heat zone can be shaped and controlled with enough precision to treat tumors even where the margin for error is measured in millimeters. Techniques such as the so-called moving shot method, hydrodissection to push critical structures away from the ablation zone, and continuous monitoring of the patient’s voice during the procedure are among the tools experienced operators use to make this possible.

The authors are careful about what their study can and cannot claim. As a retrospective cohort study, it analyzed archived routine patient data rather than randomly assigning patients to treatment arms, so it cannot rule out selection effects — the possibility that patients chosen for ablation of high-risk tumors differed in subtle ways from those with low-risk tumors. The follow-up of roughly two years on median is also shorter than the slow natural history of papillary thyroid carcinoma would ideally demand; these indolent cancers can recur many years after treatment. And the confidence intervals on the progression analysis, while statistically unremarkable, are wide enough that a modest increase in risk cannot be entirely excluded. The researchers frame their conclusions accordingly: in this retrospective cohort, no statistically significant differences in observed outcomes were detected between the high-risk and low-risk groups, and these preliminary findings support further evaluation of radiofrequency ablation performed by experienced operators in carefully selected patients.

Even with those caveats, the study lands at a consequential moment. The 2024 expert consensus has already shifted the regulatory and clinical landscape toward broader use of thermal ablation, and active surveillance — the watch-and-wait strategy pioneered for small papillary thyroid carcinomas in Japan — has established that many of these tumors can be safely observed without any intervention at all. The emerging picture is one of expanding options rather than a single replacement for surgery: observation for patients comfortable with surveillance, ablation for those who want the tumor treated but dread losing the gland, and surgery for cases where nodal disease or tumor behavior demands it. What the Zhejiang data add is evidence that the anatomical map of the thyroid, long used to draw a bright line between ablatable and non-ablatable tumors, may matter less than the skill of the operator holding the electrode. If larger, prospective studies confirm these results, the treatment of the smallest thyroid cancers may become less about where the tumor sits and more about who is treating it — a shift that could spare thousands of patients a scar, a hospital stay, and a lifetime of daily medication.

Subject of Research: Radiofrequency ablation of T1aN0M0 papillary thyroid carcinoma in high-risk anatomical locations

Article Title: Efficacy and safety of radiofrequency ablation for high-risk locations of T1aN0M0 papillary thyroid carcinoma: a retrospective cohort study

Article References: Wan, F., Xu, L., Lou, H., Shou, J., Xu, H., Li, Q., Zhou, L., Fan, G., & Li, S. (2026). Efficacy and safety of radiofrequency ablation for high-risk locations of T1aN0M0 papillary thyroid carcinoma: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17125-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17125-5

Keywords: papillary thyroid carcinoma, radiofrequency ablation, thyroid cancer, interventional radiology, high-risk location, thermal ablation, active surveillance, recurrent laryngeal nerve, T1aN0M0, retrospective cohort study, minimally invasive therapy, Zhejiang University

Focal therapies are minimally invasive treatments that use energy to destroy solid tumors while sparing surrounding healthy tissue. Surgeons and interventional radiologists can choose among thermal ablation, which cooks tumor tissue at high temperatures; cryoablation, which freezes it; and irreversible electroporation, which perforates cell membranes with pulsed electric fields until the cells die without significant heating. Beyond simply eliminating the visible tumor, clinicians have become increasingly interested in the immunogenic side effects of these techniques. When tumor cells die in particular ways, they can release antigens and danger signals that prime the immune system, potentially generating systemic responses against metastases that were never directly treated. This has fueled numerous clinical trials combining focal ablation with immune checkpoint inhibitors.

Yet a fundamental question has remained unresolved: which ablation modality produces the most immunogenic cell death, and why? Clinical decisions about which technique to use are typically based on tumor location, size, and disease stage rather than on immunological considerations, largely because direct head-to-head comparisons of the immune consequences have been scarce. The optimal dosing, timing, and pairing of ablation with immunotherapy remain largely unknown. The new study, led by researchers at the University of Minnesota, set out to answer this question with a rigorously controlled in vitro platform that isolates the interaction between treated tumor cells and the immune machinery responsible for T cell priming.

The team used melanoma cells engineered to express ovalbumin, a well-characterized model antigen, allowing them to quantitatively track every step of immune processing. They exposed the B16-OVA melanoma cells to three treatment conditions designed to ensure complete cell death: heating at 50 degrees Celsius for 30 minutes, freezing at minus 80 degrees Celsius for 30 minutes, and irreversible electroporation using 99 pulses of 50 microseconds each at 1250 volts per centimeter. The resulting cell lysates were then fed to dendritic cells grown from mouse bone marrow, and those antigen-loaded dendritic cells were co-cultured with naive T cells from OT-I transgenic mice, whose CD8 T cells carry receptors specifically tuned to the SIINFEKL peptide derived from ovalbumin.

The results were striking. When dendritic cells were loaded with lysates from electroporated tumor cells, they drove proliferation in 91.5 percent of antigen-specific T cells at the highest cell equivalent dose tested, compared with roughly 60 percent for cryoablation and 51 percent for thermal ablation. A positive control using repeated freeze-thaw cycles in liquid nitrogen pushed proliferation to 98 percent. Electroporated lysates also induced the strongest expression of CD86, a key co-stimulatory molecule on dendritic cells, indicating more robust dendritic cell maturation. In short, the manner of cell killing—not just the fact of cell death—determined how vigorously the adaptive immune response was ignited.

Paradoxically, the treatment that produced the best T cell response was not the one that released the most antigen. Cryoablation liberated the greatest quantities of total protein, ovalbumin antigen, adenosine triphosphate, and high mobility group box 1, two well-known damage-associated molecular patterns that act as immune alarm signals. Cryoablation released about 1912 micrograms per milliliter of protein, more than four times the amount released by thermal ablation, and its antigen release exceeded the electroporation condition by nearly threefold. Thermal ablation, which denatures and aggregates proteins, released the least of everything. If antigen quantity were the sole determinant of immunogenicity, cryoablation should have won.

The explanation lies in the adjuvant-like qualities of the cellular debris. When the researchers supplemented a fixed amount of ovalbumin antigen with lysates from treated B16 cells that lacked the cognate antigen, the electroporation lysates still produced the strongest dendritic cell activation and T cell proliferation, reaching 75 percent activated and proliferating T cells compared with roughly 52 percent for both cryoablation and thermal ablation. This experiment isolated the non-antigen components of the lysate—damage-associated molecular patterns, cytokines, and chemokines—and showed that they can make or break immune priming. Electroporated cells released more of the T cell chemoattractant IP-10 and less of the immunosuppressive cytokine IL-10 than the other modalities, creating a biochemical milieu that favors dendritic cell maturation and effector T cell expansion.

The study also probed whether the energy treatments altered the antigen itself. When purified ovalbumin protein and SIINFEKL peptide were exposed to the same freezing, heating, and electroporation conditions, antigen presentation and T cell activation were essentially unchanged. This suggests that the immunological differences observed with whole tumor cells stem from the complex mixture of cellular contents released upon death, not from direct modification of the antigen molecule under these conditions. The researchers note that the lyophilized ovalbumin used is mostly monomeric and may resist the conformational changes that denaturing treatments can inflict on more complex proteins, a limitation they plan to address with native protein preparations in future work.

Perhaps the most clinically provocative finding concerns dose. T cell activation in the platform saturated at a defined antigen concentration, beyond which additional antigen provided no benefit and could even impair cell viability, reflecting the finite processing capacity of antigen-presenting cells. The authors caution that overtreatment with ablation—deliberately targeting a larger tumor volume to guarantee complete destruction—may be counterproductive from an immunological standpoint. Excessive ablation can also destroy local lymphatic architecture, preventing dendritic cells from ferrying high-quality antigens to draining lymph nodes. They advocate for precision ablation that balances tumor destruction with preservation of the peritumoral immune niche, and they highlight that electroporation may offer a dual advantage by preserving molecular integrity while leaving transport pathways to the adaptive immune system intact.

The work carries important caveats. An in vitro system cannot reproduce the immunosuppressive tumor microenvironment, the wound-healing response, or the vascular and systemic inflammatory effects that clinical ablation triggers, and the ovalbumin model does not fully mirror endogenous tumor antigens. Pulse parameters also matter: recent studies show that varying pulse width and frequency can shift cell death between apoptotic and pyroptotic programs, each with distinct immunological consequences. Still, by demonstrating that the fundamental quality of the immunogenic signal—not merely its quantity—determines immune priming, the study provides a mechanistic foundation for engineering focal therapies as in situ tumor vaccines and for rationally selecting which energy modality to pair with checkpoint blockade in the clinic.

Subject of Research: Comparative immunogenicity of focal tumor ablation modalities and their effects on antigen presentation and T cell activation

Article Title: Focal therapeutic conditions matter: How energy affects antigen presentation and T cell activation

Article References: Jiang, M., Shao, Q., Vallin, J., Shimizu, Y., Burbach, B., Azarin, S., & Bischof, J. (2026). Focal therapeutic conditions matter: How energy affects antigen presentation and T cell activation. Bioengineering & Translational Medicine, 11(5), Article e70152. https://doi.org/10.1002/btm2.70152

Image Credits: AI Generated

DOI: 10.1002/btm2.70152

Keywords: irreversible electroporation, cryoablation, thermal ablation, focal therapy, dendritic cells, T cell activation, antigen presentation, immunogenic cell death, damage-associated molecular patterns, cancer immunotherapy, B16 melanoma model, immune checkpoint inhibitors

The core idea behind interventional oncology is deceptively simple: if you can see a tumor clearly under imaging, you can often treat it without opening the body. High-resolution computed tomography, ultrasound, and magnetic resonance imaging allow physicians to navigate instruments to lesions deep within organs, destroying or starving them with millimeter-level precision. What began decades ago with image-guided biopsies, using needles to sample suspicious tissue, has evolved into a therapeutic arsenal of remarkable sophistication. The field’s trajectory, the authors note, illustrates the accelerating pace of innovation in oncology, transforming procedures that once seemed impossible into routine clinical practice.

Among the most consequential of these techniques is trans-arterial embolization, which has reshaped the treatment of liver cancer in particular. Rather than flooding the entire body with chemotherapy, interventionalists thread a catheter through the arterial system until its tip reaches the vessel feeding the tumor. Therapeutic agents are then delivered directly into that blood supply, often combined with particles that block the vessel altogether, cutting off the tumor’s nourishment. The approach delivers a concentrated payload to the malignancy while sparing functional liver tissue, a critical consideration in an organ whose reserve capacity often determines whether a patient can tolerate further treatment.

Equally transformative are percutaneous ablation techniques, in which needles or probes are placed directly into tumors and used to destroy them in situ. Thermal ablation, the most widely used family of methods, kills cancer cells by applying extreme heat through radiofrequency energy or microwaves, or by freezing tissue with cryoablation. These procedures have opened new pathways for patients who might otherwise have been poor candidates for invasive surgery, whether because of tumor location, coexisting illness, or insufficient organ reserve. Crucially, the authors emphasize, such advances have not merely provided alternatives to conventional treatment; they have created entirely new therapeutic possibilities, both for previously untreatable conditions and for combination strategies that make curative approaches achievable for more patients.

Perhaps the most scientifically exciting frontier lies at the intersection of interventional oncology and immunotherapy, the class of drugs that unleashes the body’s own immune defenses against cancer. Recent discoveries have revealed that many interventional procedures do more than physically destroy tumor tissue; they can actively stimulate a systemic immune response. When thermal ablation breaks down tumor cells, it releases tumor antigens, molecular fingerprints that the immune system can recognize and remember. In some patients this triggers a phenomenon known as the abscopal effect, in which the local treatment of one lesion appears to provoke immune-mediated regression of untreated tumors elsewhere in the body. The effect offers tantalizing avenues for combination therapies that pair targeted physical intervention with immunological activation, and research into this synergy is one of the field’s most active areas.

The growing power of interventional oncology is inseparable from its integration into the multidisciplinary machinery of modern cancer care. Interventional oncologists now sit regularly on tumor boards, the committees where medical oncologists, surgical oncologists, radiation oncologists, and other specialists jointly design each patient’s therapeutic strategy. This collaboration has produced more nuanced and personalized treatment sequences. Interventional procedures can be used to downstage tumors, shrinking them so that curative surgery becomes feasible, or to treat residual disease and oligoprogression, the isolated growth of a few lesions after conventional therapy has otherwise controlled the cancer. The ability to interleave treatments in this way has measurably improved outcomes and expanded options for patients who once faced limited choices.

Looking forward, the technological horizon appears remarkably bright. Artificial intelligence and machine learning are enhancing the precision of image-guided procedures, helping clinicians plan trajectories and interpret imaging with increasing accuracy. Robotic systems are extending the reach and steadiness of interventional techniques beyond what human hands alone can achieve, while advanced imaging technologies now provide real-time views of tumor biology and treatment response. Nanotechnology and molecular medicine are opening new frontiers in targeted therapy delivery, promising treatments that are more precise, more effective, and more personalized than ever before. The convergence of these computational, robotic, and biological tools suggests that the next decade of interventional oncology may be even more transformative than its last.

The field’s progress, however, is not without obstacles. Pereira and Helmberger are candid about the challenges ahead: the discipline must continue to strengthen its evidence base through rigorous clinical trials, and quality assurance frameworks need to be standardized across institutions. One concrete response is the International Accreditation System for Interventional Oncology Services, known as IASIOS, which aims to certify that centers performing these procedures meet consistent standards of training, equipment, and patient care. Training programs must also evolve, and the visibility of interventional oncology among medical students and fellows must grow to meet the rising demand for skilled interventionalists. The COVID-19 pandemic, though deeply disruptive, accelerated certain aspects of the field’s development, as supportive and palliative interventions and telemedicine-guided procedures gained prominence when conventional care pathways were strained.

Scholarly publishing has a role to play in sustaining this momentum, and the launch of CVIR Oncology itself reflects the field’s maturation. The journal is designed as a bridge between oncological specialties, welcoming contributions from interventional radiologists, medical and surgical oncologists, radiation oncologists, and basic scientists alike. The editorial logic is that cross-disciplinary dialogue breaks down silos: a surgical oncologist’s insights on post-procedural outcomes can refine interventional techniques, just as an immunologist’s findings can enhance procedural efficacy. By publishing both basic science and clinical research, the journal aims to translate laboratory discoveries into practical therapies, supporting the shift toward personalized medicine. As an open-access publication, it also ensures that practitioners in resource-limited settings can access the same evidence base as those in major academic centers.

Ultimately, the promise of interventional oncology extends beyond its technical achievements to something more human: the quality of patients’ lives. By offering less invasive treatments with fewer complications and shorter recovery times, the field is making cancer therapy more tolerable, benefiting patients and society alike. From primary liver and kidney tumors to metastatic disease, and from palliative symptom control to curative intent, interventional oncology is redefining what is possible across the entire spectrum of malignancy. The story, as its pioneers tell it, is one of continuous innovation and adaptation, and as the field stands on the threshold of new discoveries, its practitioners are confident that it will play an increasingly vital role in a future where cancer treatment is not only more effective, but also more humane.

Subject of Research: The evolution of interventional oncology as a minimally invasive, image-guided fourth pillar of multidisciplinary cancer treatment

Article Title: The evolution of interventional oncology: pioneering a new era in cancer care

Article References: Pereira, P. L., & Helmberger, T. (2025). The evolution of interventional oncology: pioneering a new era in cancer care. CVIR Oncology, 1(1), Article 1. https://doi.org/10.1007/s44343-025-00002-6

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00002-6

Keywords: interventional oncology, interventional radiology, thermal ablation, trans-arterial embolization, immunotherapy, abscopal effect, liver cancer, artificial intelligence, multidisciplinary cancer care, IASIOS accreditation, minimally invasive treatment, CVIR Oncology

The study, conducted at a single center between May 2008 and February 2020, followed 48 consecutive patients who were treated for a total of 53 biopsy-confirmed papillary renal cell carcinoma tumors. These were not healthy surgical candidates: the patients had been deemed unfit for partial nephrectomy, the current gold-standard operation for localized kidney cancer, because of advanced age, impaired kidney function, or poor overall condition, while some had simply declined surgery. Every case was reviewed by a multidisciplinary tumor board that included urologists, oncologists, radiologists, pathologists, and radiation oncologists before cryoablation was chosen. The cohort was predominantly male, with 39 men and 9 women, and the median age was 69.5 years, with patients ranging from 36 to 88 years old.

Papillary renal cell carcinoma is a distinct entity within the family of kidney cancers. While clear cell renal cell carcinoma is the most common histological type, papillary tumors account for roughly 10 to 15 percent of all renal cell carcinomas and are generally associated with better outcomes. The World Health Organization formally listed the entity in its 2016 classification of renal tumors, and pathologists further divide papillary tumors into two subtypes: type 1, which tends to be slower growing and more indolent, and type 2, which carries more aggressive features such as higher tumor grade, necrosis, and lymphovascular invasion. In the French series, type 1 tumors dominated the cohort, making up 46 of the 53 lesions, or 88.8 percent, while type 2 tumors accounted for the remaining 11.2 percent.

The technical execution of the procedure reveals why cryoablation has become such a powerful tool in interventional oncology. All treatments were performed by experienced interventional radiologists under general anesthesia or sedation, with the patient staying in hospital. Using computed tomography or magnetic resonance imaging for guidance, the radiologists inserted between two and four thin cryoprobes, typically 15 to 17 gauge, directly through the skin and into the tumor. The number, type, and positioning of the probes were tailored to each tumor’s size, location, and morphology, with the goal of enveloping the entire tumor in a lethal ice ball that extended 5 to 10 millimeters beyond its visible margins. For MRI-guided procedures, the team used MRI-compatible probes and near real-time multiplanar MRI fluoroscopy, allowing them to watch the ice ball grow in three dimensions as it formed.

Each ablation followed a standardized freeze-thaw protocol: two freezing cycles of 10 minutes each, separated by a 10-minute passive thawing period. This repetition is critical to the biology of cryodestruction. Rapid freezing causes ice crystals to form inside and around cells, rupturing their membranes, while the thawing and refreezing cycles amplify vascular damage, cutting off the tumor’s blood supply and ensuring that cells at the margin of the ice ball, where temperatures are less extreme, are still lethally injured. When tumors sat close to vulnerable structures such as the bowel or the abdominal wall, the team performed hydro-dissection or pneumo-dissection, injecting fluid or gas to physically push those organs out of harm’s way. In one striking example described in the study, sterile gloves filled with warm saline were placed over the skin at the probe entry sites to prevent frostbite, because MRI-compatible cryoprobes are not insulated along their shafts.

The results were striking on nearly every measure. Technical efficacy, defined as the absence of contrast enhancement and tumor enlargement on imaging within three months of the procedure, was achieved in all 53 tumors, a 100 percent success rate in destroying the treated lesion. The overall complication rate was just 11 percent, and every single complication was minor, classified as grade 2 or lower on the standard Clavien-Dindo scale. No patient required hemodialysis after treatment, a crucial finding given that many of these patients already had compromised kidney function, and a quarter of the cohort had only a single kidney. The median hospital stay was three days, and the median procedure took 127 minutes.

Oncologic outcomes were equally impressive. Only three of the 53 tumors, or 5.7 percent, recurred locally during follow-up, with a mean time to recurrence of 36 months. Two of the recurrences occurred in type 1 tumors and one in a type 2 tumor, a difference that was not statistically significant but is consistent with the known biology of the more aggressive type 2 subtype, which in this study also carried higher International Society of Urologic Pathologists grade scores. Two of the three recurrences were successfully treated with a second cryoablation. When these salvage treatments were factored in, the five-year estimates for local recurrence-free survival reached 95.9 percent for primary treatment and 97.8 percent for secondary effectiveness. Most remarkably, cancer-specific survival and metastasis-free survival were both 100 percent: no patient died of papillary renal cell carcinoma, and no patient ever developed distant metastases. Overall survival at five years was 90.3 percent, with the deaths that did occur attributable to unrelated cancers such as gastric, lung, and duodenal malignancies.

Perhaps the most provocative comparison in the study is with surgery itself. The authors point to a large surgical series of 626 patients with papillary renal cell carcinoma treated with partial nephrectomy, in which five-year cancer-specific survival was 83 percent, local recurrence-free survival was 91 percent, and overall survival was 82 percent, all figures lower than those reported in the cryoablation cohort. The authors are careful to caution against overinterpreting this comparison: there was no direct head-to-head analysis, the surgical series involved larger tumors averaging 4 to 5 centimeters compared with 2 to 3 centimeters in the ablation studies, and the sample sizes differ dramatically. Still, the findings add to a growing body of evidence that thermal ablation can match surgical outcomes for early-stage kidney tumors while avoiding the risks of major surgery, with prior studies showing fewer complications and shorter hospital stays for ablated patients.

The study does carry limitations that the authors acknowledge candidly. Its retrospective design and relatively small sample size, a consequence of the rarity of papillary renal cell carcinoma compared with the clear cell type, mean that larger multicenter studies will be needed to confirm the results. The effect of operator experience was not formally evaluated, although the authors note that their center performs more than 60 renal cryoablations per year, suggesting a consistently high standard of practice. The potential for inter- and intra-observer variability in imaging assessments was also not eliminated. And because the cohort was dominated by type 1 tumors, the findings for the more aggressive type 2 subtype rest on only seven lesions, a reminder that subtype-specific evidence remains thin.

Even with those caveats, the message for clinical practice is clear. For patients with biopsy-confirmed, localized papillary renal cell carcinoma who cannot undergo or decline surgery, percutaneous cryoablation delivered under image guidance offers a treatment that is safe, kidney-preserving, and, on the evidence of five years of follow-up, extraordinarily effective. The authors suggest that when treating type 2 tumors, radiologists should aim for larger ablation safety margins to account for their more aggressive biology. As interventional oncology continues to mature, they argue, cryoablation for renal cell carcinoma, particularly for indolent histologic subtypes like papillary tumors, deserves increased consideration in clinical practice and in future guideline development. For a disease increasingly caught early by incidental imaging, the freezer may prove to be as mighty as the scalpel.

Subject of Research: Percutaneous cryoablation as a treatment for papillary renal cell carcinoma

Article Title: Safety and oncologic efficacy of percutaneous cryoablation of papillary renal cell carcinoma: a 5-year single-center follow-up study

Article References: Mulot, B.-M., de Marini, P., Tan, A. S. M., Orkut, S., Garnon, J., Weiss, J., Autrusseau, P. A., Tricard, T., Lang, H., Cazzato, R. L., & GANGI, A. (2025). Safety and oncologic efficacy of percutaneous cryoablation of papillary renal cell carcinoma: a 5-year single-center follow-up study. CVIR Oncology, 1(1), Article 4. https://doi.org/10.1007/s44343-025-00003-5

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00003-5

Keywords: cryoablation, papillary renal cell carcinoma, kidney cancer, interventional radiology, renal tumors, minimally invasive treatment, oncology, MRI guidance, CT guidance, cancer survival, thermal ablation, nephron-sparing

The technique, known as spinal laser interstitial thermal therapy, or sLITT, involves threading thin laser fibers through a small percutaneous channel directly into a tumor, then destroying it from the inside with precisely controlled heat. Real-time magnetic resonance thermography tracks temperature continuously during the procedure, and an Arrhenius damage model estimates tissue destruction on the treatment workstation as a color-coded overlay on anatomical images. Up to six temperature-monitoring points are placed at the interface between the epidural tumor and the dura mater, the protective membrane covering the spinal cord. When the interface approaches a safety threshold of approximately 50 degrees Celsius, the system automatically shuts the laser off, protecting the cord and nerve roots from thermal injury.

One of the most striking technical challenges the team had to solve involves breathing itself. Respiratory motion degrades the reliability of the thermal map, so ablations are delivered in cycles under ventilatory arrest. Patients are preoxygenated to 100 percent oxygen saturation, each ablation cycle is capped at 100 seconds, and ventilation resumes between cycles. If oxygen saturation falls below 94 percent or the dura-interface temperature threshold is reached, the procedure halts immediately. Each laser fiber produces a zone of thermal damage extending roughly 5 millimeters radially, and additional access cannulas are placed in tandem when greater coverage along the spine is needed. It is a delicate choreography of neurosurgery, physics, and anesthesiology performed inside an intraoperative MRI suite.

The new report, led by Sumeeth V. Jonathan and senior author Claudio E. Tatsui, describes the largest clinical experience with sLITT for chordoma to date: four patients treated across five procedures between January 2016 and November 2025. The tumors spanned the full anatomic range of the disease, including metastatic foci from primary sacral, clival, and cervical chordomas, plus one primary thoracic lesion. Four procedures served as salvage therapy after prior surgery, radiotherapy, or systemic treatment had failed, while one patient received sLITT as primary treatment specifically to avoid the morbidity of open surgery. Median time from diagnosis to LITT was 19.1 months, and all patients entered treatment with excellent functional status, with Karnofsky Performance Status scores of 90 to 100.

Procedurally, the team used a median of four laser fibers and 16 ablations per case, delivering power between 12 and 15 watts. Median case duration was 352.5 minutes, and patients went home after a median hospital stay of just two days. Postoperative stereotactic radiosurgery, a highly focused form of radiation, was administered after all but one procedure, at a median of 7.5 days after LITT. Only one complication occurred: a transient episode of proximal arm radiculopathy that resolved completely with a short course of steroids by the one-month follow-up. There was no procedure-related mortality and no other perioperative complications.

The oncologic results were encouraging. Every patient showed volumetric tumor shrinkage on the earliest postoperative MRI, obtained at a median of 4.2 months, with a mean volume reduction of 25.7 percent. More importantly, by the conventional endpoint of freedom from local progression, meaning no radiographic growth and no further intervention at the treated site, no treated lesion progressed or required additional treatment during available follow-up, which extended to a median of 16.8 months and reached 48.1 months in the longest-followed case. Median overall survival from LITT was 23.0 months. Two patients had died by last follow-up, typically from disease progressing elsewhere in the body, while two remained alive.

A systematic review of the literature performed by the authors found only four previously published case reports of LITT for chordoma, three of which described complete thermal ablation with radiographic response. Those reports used remarkably varied approaches, including endoscopic endonasal, percutaneous translaminar, and transcranial catheter placement, reflecting the anatomic diversity of chordoma across the skull base and spine. No major complications were reported in any of them. The new series more than doubles the aggregate published experience and is the first to report volumetric outcomes and local control systematically across multiple patients.

Two biological questions have long shadowed the idea of laser-ablating chordomas. First, the tumor’s characteristic lipid-rich physaliferous cells were hypothesized to conduct heat poorly compared with other ablated tumor types, potentially limiting ablation size. Yet intraoperative thermography in prior work demonstrated spherical ablation zones of 14 to 16 millimeters in axial diameter, comparable to those achieved in other histologies, suggesting the theoretical concern is not clinically significant. Second, because chordomas are notorious for seeding tumor along biopsy and surgical tracts, researchers worried the percutaneous laser trajectory could do the same. That risk was mitigated with an outer access cannula that isolates the tract from direct tumor contact, and no tract seeding has been observed on follow-up imaging.

The authors are careful about what these data can and cannot show. Because radiosurgery followed four of the five procedures, the independent contribution of LITT cannot be separated from that of radiation in this retrospective design. Still, several observations hint that the laser is doing real work: the one procedure not followed by radiosurgery nonetheless showed volumetric reduction, and shrinkage appeared on scans as early as 2.8 months, a timeframe consistent with the immediate ablative effect of heat rather than the slower radiobiological response to radiation. Prior large sLITT series in metastatic disease, including one of 129 patients treated across 144 thoracic segments, found that patients treated with LITT alone achieved one-year local control of 83.4 percent, statistically similar to those who also received radiotherapy.

The researchers position sLITT as a complement to, not a replacement for, established therapies. Repeat resection remains the most definitive local treatment but carries high complication rates in previously irradiated fields, and reirradiation is constrained by cumulative dose to the spinal cord and other organs at risk. The realistic niche for sLITT is narrow but meaningful: local tumor reduction and decompression in patients whose lesions sit in previously treated fields, who need to resume systemic therapy quickly, or for whom open surgery is too risky. Intriguingly, the team also raises a forward-looking hypothesis. Chordoma harbors an immune-excluded microenvironment in which stromal barriers wall off effector immune cells, and LITT-induced hyperthermia has been shown in other tumors to release damage-associated molecular patterns and transiently open the blood-brain barrier, potentially converting immunologically cold tumors into hot ones. Whether laser ablation could help unlock chordoma’s defenses against immunotherapy remains untested, but it offers one more reason this small proof-of-concept study may mark the beginning of a much larger story.

Subject of Research: MRI-guided spinal laser interstitial thermal therapy as a minimally invasive treatment for chordoma

Article Title: Spinal laser interstitial thermal therapy for treatment of chordoma: single-center experience and literature review

Article References: Jonathan, S. V., Chen, J. W., Wu, K., Flores, A. R., Ghia, A. J., Kimchi, G., North, R. Y., Alvarez-Breckenridge, C. A., Rhines, L. D., & Tatsui, C. E. (2026). Spinal laser interstitial thermal therapy for treatment of chordoma: single-center experience and literature review. Journal of Neuro-Oncology, 179(2), Article 59. https://doi.org/10.1007/s11060-026-05764-4

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05764-4

Keywords: chordoma, laser interstitial thermal therapy, LITT, spinal tumor, MRI thermometry, stereotactic radiosurgery, neurosurgery, MD Anderson, salvage therapy, thermal ablation, tumor microenvironment, Journal of Neuro-Oncology